🚨Trade Alert 🚨 BCTX

🚨Trade Alert 🚨 BCTX͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ ͏ ‌ A $25 price target offers the potential for this quietly trading biotech company to more than TRIPLE in share price! Greetings All, Oncology, immunology, cardiovascular diseases…. These are some of the top focuses in the biotech arena. Even though there has been significant progress in treating cancer, it is not enough. The disease remains the second-largest cause of death in the United States. [Over 600,000 deaths](~/AASl5QA~/RgRmfUY3P0SlaHR0cHM6Ly93d3cubXVuaWNocmUuY29tL3VzLWxpZmUvZW4vcGVyc3BlY3RpdmVzL21pc3NlZC1jYW5jZXItc2NyZWVuaW5ncy1mcm9tLWNvdmlkLmh0bWw_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmNRcDhMdFEteTVYSTN2aVlsNXV3Y043eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmSRN8GaZNQuvyZSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAXhsQ~~) are expected from cancer this year alone. In fact, every year that is about how many people die from the disease. If you’ve had cancer or know someone who’s had cancer, you know just how horrible a disease this is. It’s also a huge financial cost that is growing rapidly. Many biotech companies are racing to help find answers to treating the disease and to help save lives. With that said, make sure BriaCell Therapeutics Corp. (NASDAQ: BCTX) is on your radar! This immune-oncology-focused biotech is beginning to capture some major Wall Street attention and is only at the beginning stages of its growth story. We all know that with every problem comes an opportunity -- in this case, a massive opportunity for investors to be a part of small companies that are developing new ways to treat cancer. BCTX is a little-known oncology play on the NASDAQ that currently holds [a whopping high $25 price target!](~/AASl5QA~/RgRmfUY3P4QJAWh0dHBzOi8vbW9uZXkuY25uLmNvbS9xdW90ZS9mb3JlY2FzdC9mb3JlY2FzdC5odG1sP3N5bWI9QkNUWCZfa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2Y1FwOEx0US15NVhJM3ZpWWw1dXdjTjd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaEwjOn46dGV4dD1CcmlhY2VsbCUyMFRoZXJhcGV1dGljcyUyMENvcnAlMjAoTkFTREFRJTNBQkNUWCkmdGV4dD1UaGUlMjAyJTIwYW5hbHlzdHMlMjBvZmZlcmluZyUyMDEyLHRoZSUyMGxhc3QlMjBwcmljZSUyMG9mJTIwNi4xNC5XA3NwY0IKZJE3wZpk1C6_JlIbdHJpc3RyYW1iYWxkd2luODlAZ21haWwuY29tWAQABeGx) That’s over 250% in potential upside compared to current trading levels! Additionally, BULLish ratings are piling up on the company with a “STRONG BUY” from [Investing.com](~/AASl5QA~/RgRmfUY3P0SfaHR0cHM6Ly93d3cuaW52ZXN0aW5nLmNvbS9lcXVpdGllcy9icmlhY2VsbC10aGVyYXBldXRpY3MtY29ycC10ZWNobmljYWw_Y2lkPTExNzAzNTkmX2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmNRcDhMdFEteTVYSTN2aVlsNXV3Y043eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmSRN8GaZNQuvyZSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAXhsQ~~) and [NASDAQ.com.](~/AASl5QA~/RgRmfUY3P0SPaHR0cHM6Ly93d3cubmFzZGFxLmNvbS9tYXJrZXQtYWN0aXZpdHkvc3RvY2tzL2JjdHgvYW5hbHlzdC1yZXNlYXJjaD9fa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2Y1FwOEx0US15NVhJM3ZpWWw1dXdjTjd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaExXA3NwY0IKZJE3wZpk1C6_JlIbdHJpc3RyYW1iYWxkd2luODlAZ21haWwuY29tWAQABeGx) The stock also currently has a “HOLD” rating at [BarChart.com.](~/AASl5QA~/RgRmfUY3P0SAaHR0cHM6Ly93d3cuYmFyY2hhcnQuY29tL3N0b2Nrcy9xdW90ZXMvQkNUWC9vdmVydmlldz9fa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2Y1FwOEx0US15NVhJM3ZpWWw1dXdjTjd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaExXA3NwY0IKZJE3wZpk1C6_JlIbdHJpc3RyYW1iYWxkd2luODlAZ21haWwuY29tWAQABeGx) AstraZeneca, Gilead Sciences, BeiGene, and Moderna… are some of the biggest and most promising companies in the oncology market. But have you seen their market caps? While their growth has been impressive, you would be hard-pressed to see them generate astronomical returns quickly at their current share prices. Not to say that they still don’t have room for upside themselves. BCTX currently boasts a market cap of just around $100M which leaves substantial room for growth. With a mission to develop novel immunotherapies to fight cancer and improve patients’ lives whose medical needs are currently unmet, this is a company worth keeping a very close eye on! Last month BCTX had some big news, announcing that the company has entered into an arrangement agreement with BriaPro Therapeutics Corp. (“SpinCo”), a wholly-owned subsidiary of the Company pursuant to which certain pre-clinical pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer will be spun-out to SpinCo by way of a court approved statutory plan of arrangement under the Business Corporations Act (British Columbia). Why is this significant? As BCTX focuses its efforts on the upcoming pivotal study of its lead clinical candidate, Bria-IMT™, in advanced metastatic breast cancer, the company believes this strategy of spinning out certain pre-clinical immunotherapies in a separate entity of BriaPro Therapeutics Corp. will position them for success and will create shareholders value over the long term. The company also announced last month that it has completed the previously-announced strategic investment by [Prevail Partners, LLC](~/AASl5QA~/RgRmfUY3P0SdaHR0cHM6Ly9maW5hbmNlLnlhaG9vLmNvbS9uZXdzL2JyaWFjZWxsLWNsb3Nlcy00LW1pbGxpb24tc3RyYXRlZ2ljLTE1MzgwMDI5OS5odG1sP19reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZjUXA4THRRLXk1WEkzdmlZbDV1d2NON3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpkkTfBmmTULr8mUht0cmlzdHJhbWJhbGR3aW44OUBnbWFpbC5jb21YBAAF4bE~) in accordance with a stock purchase agreement entered into between BriaCell and Prevail Partners on May 12, 2023. Contract Research Organizations (CROs) typically do not invest in small biotech companies so this screams in volumes. Prevail Partner’s significant investment in BCTX is a remarkable sign of confidence in the company’s clinical plans and objectives! “Our top priority remains to bring our novel therapeutic to advanced breast cancer patients who have failed other treatments and/or are unable to tolerate the harsh side effects of other drugs, and we believe Prevail is the right partner for us to achieve this goal,” commented Dr. William V. Williams, BriaCell’s President & CEO. Advanced breast cancer mainly affects women, but men can get it, too. For anyone, it can turn life upside down. There's no cure for the disease. BCTX recently revealed data that highlights the potential clinical value of the company’s Bria-MT™ regimen in patients with advanced metastatic breast cancer after receiving multiple prior therapies. “Our clinical findings continue to confirm our approach for our upcoming pivotal trial of Bria-IMT™ combination regimen,” commented Dr. William V. Williams. “BriaCell’s regimen has shown robust clinical efficacy, better than expected survival outcomes, and an excellent safety profile in this very difficult to treat patient cohort. We are seeing benefits in patients who failed other treatments and/or cannot tolerate the harsh side effects of other therapies.” Awarded [Fast Track status by the U.S. Food and Drug Administration (FDA)](~/AASl5QA~/RgRmfUY3P0SUaHR0cHM6Ly9mZWVkcy5pc3N1ZXJkaXJlY3QuY29tL25ld3MtcmVsZWFzZS5odG1sP25ld3NpZD03MDI4OTk4NTgzOTczMjg4Jl9reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZjUXA4THRRLXk1WEkzdmlZbDV1d2NON3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpkkTfBmmTULr8mUht0cmlzdHJhbWJhbGR3aW44OUBnbWFpbC5jb21YBAAF4bE~), Bria-IMT™, is being evaluated in a [Phase II](~/AASl5QA~/RgRmfUY3P0R7aHR0cHM6Ly9jbGluaWNhbHRyaWFscy5nb3YvY3QyL3Nob3cvTkNUMDMzMjgwMjY_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmNRcDhMdFEteTVYSTN2aVlsNXV3Y043eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmSRN8GaZNQuvyZSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAXhsQ~~)randomized clinical trial in advanced metastatic breast cancer (i.e. breast cancer that has spread beyond the breast to other tissues). The company’s immunotherapy remarkably boosts the ability of the body's own cancer fighting cells to find and destroy cancerous tumors…. This is game-changing!The fact that BCTX already has a green light from the FDA for Fast Track Status is enough to want to keep the stock at the top of your watch list. Keep an eye out for any developments as the company progresses towards a pivotal study initiation for Bria-IMT in combination with an immune checkpoint inhibitor in advanced metastatic breast cancer. BCTX may be one of the hottest biotech companies going under the radar in 2023 and could be trading at a supreme value right now as it sets out to become a leader in the cancer treatment revolution! [(~/AASl5QA~/RgRmfUY3P0RhaHR0cHM6Ly9icmlhY2VsbC5jb20vP19reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZjUXA4THRRLXk1WEkzdmlZbDV1d2NON3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpkkTfBmmTULr8mUht0cmlzdHJhbWJhbGR3aW44OUBnbWFpbC5jb21YBAAF4bE~) NASDAQ: BCTX Developing Novel Therapies to Destroy Cancer Focusing initially on breast cancer, BriaCell Therapeutics Corp. (Nasdaq: BCTX) is dedicated to enhancing the lives of people with cancer with limited therapy options by developing novel immunotherapies to fight cancer. Immunotherapies have become the forefront of cancer treatments because they use the body’s immune system to destroy cancer cells, offer the potential for higher levels of safety and efficacy than chemotherapy, and may also prevent cancer recurrence. Any investor interested in the science scene should take a close look at the oncology arena on Wall Street. Coming in only after cardiovascular disease, cancer is the second leading cause of death in this world. Precedence Research projects that the global oncology market will increase at a compound annual growth rate of 8.2 percent to reach [US$581.25 billion in 2030!](~/AASl5QA~/RgRmfUY3P0TRaHR0cHM6Ly93d3cucHJlY2VkZW5jZXJlc2VhcmNoLmNvbS9vbmNvbG9neS1tYXJrZXQ_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmNRcDhMdFEteTVYSTN2aVlsNXV3Y043eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMIzp-OnRleHQ9VGhlJTIwZ2xvYmFsJTIwb25jb2xvZ3klMjBtYXJrZXQlMjB3YXMsdG90YWwlMjBtYXJrZXQlMjBzaGFyZSUyMGluJTIwMjAyMS5XA3NwY0IKZJE3wZpk1C6_JlIbdHJpc3RyYW1iYWxkd2luODlAZ21haWwuY29tWAQABeGx) A Collaboration with Incyte Corporation: BCTX currently has a non-exclusive clinical trial collaboration with Incyte Corporation (Nasdaq: INCY) to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte and BriaCell will evaluate novel combinations of compounds from Incyte’s development portfolio with BriaCell’s drug candidates in advanced breast cancer patients. Small Molecule Program BriaCell’s small molecule program consists of novel selective protein kinase C delta inhibitors that have shown activity in pre-clinical models of several cancers and fibrotic diseases. To reiterate… [BriaCell recently announced a positive end of Phase II meeting with the FDA for Bria-IM™ combination in Advanced Metastatic Breast Cancer](~/AASl5QA~/RgRmfUY3P0SUaHR0cHM6Ly9mZWVkcy5pc3N1ZXJkaXJlY3QuY29tL25ld3MtcmVsZWFzZS5odG1sP25ld3NpZD03MzAzNDc1NzU2MDQ2ODQ0Jl9reD1fLUhTcG8yeTlsRFdKZTVmSzZ4MzZjUXA4THRRLXk1WEkzdmlZbDV1d2NON3lwNV9vMzd3Tm9JTXpOVDBsMkRYLlRhOXJoTFcDc3BjQgpkkTfBmmTULr8mUht0cmlzdHJhbWJhbGR3aW44OUBnbWFpbC5jb21YBAAF4bE~) Following a successful completion of a Phase I study showing a favorable safety profile for the combination regimen, BriaCell is conducting a Phase II clinical trial of BriaCell’s lead candidate, Bria-IMT™, awarded Fast Track status by the U.S. Food and Drug Administration (FDA), in combination with retifanlimab (INCMGA00012), an anti-PD-1 antibody (provided by Incyte). The combination study is listed on ClinicalTrials.gov as [NCT03328026](~/AASl5QA~/RgRmfUY3P0R7aHR0cHM6Ly9jbGluaWNhbHRyaWFscy5nb3YvY3QyL3Nob3cvTkNUMDMzMjgwMjY_X2t4PV8tSFNwbzJ5OWxEV0plNWZLNngzNmNRcDhMdFEteTVYSTN2aVlsNXV3Y043eXA1X28zN3dOb0lNek5UMGwyRFguVGE5cmhMVwNzcGNCCmSRN8GaZNQuvyZSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAXhsQ~~). Bria-OTS™*: Recently awarded a patent by the USPTO, BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized immunotherapy for the treatment for advanced stage breast cancer. In November 2020, BCTX announced a Cooperative Research and Development Agreement with the National Cancer Institute (NCI, Center for Cancer Research), part of the National Institutes of Health, to investigate the mechanism of action of novel off-the-shelf personalized therapeutics for cancer. BREAST CANCER: FACTS & STATISTICS - According to a report published by the American Cancer Society in 2023, approximately 609,820 Americans are expected to die from cancer in 2023 (approximately 1,670 deaths per day), making cancer the second leading cause of death in the U.S., exceeded only by heart disease. - As of January 2023, the number of women in the U.S. with a history of invasive breast cancer is estimated to be 3.1 million (excluding the estimated 284,200 new cases in 2023). This number is expected to increase by 12% to 4 million in 2024. Approximately 30% of breast cancers occur in women younger than age 50 and 44% occur in women older than age 65. - According to an American Cancer Society in 2023 fact sheet, 297,790 women and 2,800 men are expected to be diagnosed with invasive breast cancer in 2023 in the U.S. alone. Breast cancer is the most frequently-diagnosed cancer in women in the U.S. - Breast cancer deaths in 2023 are estimated to be 43,700 (43,170 women, 530 men), making breast cancer the second leading cause of cancer death in women (after lung cancer). - As reported by the American Cancer Society in 2023, approximately 62% of breast cancer cases are detected at the early stages (i.e., the cancer is found in the breast tissue, and has not spread to lymph nodes or other regions of the body), for which the 5-year survival rate is estimated to be 99%. As soon as the cancer spreads to lymph nodes under the arm or nearby tissues (regional stage), the 5-year survival rate drops to 85%. However, once the cancer spreads to other lymph nodes or body parts (distant stage or metastatic cancer), the 5-year survival rate falls to as low as 27% (i.e. 73% of the patients die within 5 years). This shows the significant need for effective treatments for this deadly cancer. BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR…. - 15 of 18 patients remain alive of those recruited since the study reopened in 2021. - Longer than expected patient survival data highlights tolerability and clinical effectiveness of BriaCell’s combination treatment. - The Bria-IMT™ combination regimen activated the immune system even in anergic patients with very weak immune systems. - Continued positive clinical data suggests more meaningful survival and clinical benefits in advanced metastatic breast cancer. Dr. William V. Williams, BriaCell’s President and CEO commented, “With over 40,000 annual deaths in the U.S. alone, advanced metastatic breast cancer remains an unmet medical need. Patients who have only months to live tend to avoid current therapies that are proven ineffective and are associated with excessive toxicities. BriaCell’s regimen has shown robust clinical efficacy, better than expected survival outcomes, and an excellent safety profile in this very difficult to treat patient cohort. We are seeing benefits in patients who failed other treatments and/or cannot tolerate the harsh side effects of other therapies.” In Summary… The optimism is clear for this emerging biotech company and all eyes are looking for developments about Bria-IMT. Developments in the company’s clinical data could be just the catalyst needed to send the stock soaring. Bria-IMT is the largest source of optimism for the company’s commercial ambitions. Why is this study so critical? [1 in 8 women](~/AASl5QA~/RgRmfUY3P0T1aHR0cHM6Ly93d3cubWV0YXZpdm9yLm9yZy9tYmMtcHJlcC9tZXRhc3RhdGljLWJyZWFzdC1jYW5jZXItc3RhdGlzdGljcy8_Z2NsaWQ9Q2p3S0NBandsNk9pQmhBMkVpd0F1VXdXWlQ4c0FmSms4TkJVWDVUSG9LNGFaUVZ2LWUwZjNRcWtnMVRuWE5fVmFZS21yOTFrTmdPeEV4b0MtcllRQXZEX0J3RSZfa3g9Xy1IU3BvMnk5bERXSmU1Zks2eDM2Y1FwOEx0US15NVhJM3ZpWWw1dXdjTjd5cDVfbzM3d05vSU16TlQwbDJEWC5UYTlyaExXA3NwY0IKZJE3wZpk1C6_JlIbdHJpc3RyYW1iYWxkd2luODlAZ21haWwuY29tWAQABeGx) will be diagnosed with breast cancer & 1 in 3 of those will become metastatic. BriaCell and the FDA have agreed on the primary end point, the essential elements of the study design, and the type of patients to be enrolled in BriaCell’s upcoming pivotal clinical study. This pivotal registration study will be enrolling advanced metastatic breast cancer patients for whom no approved treatment options exist. Registration study success could lead to a Biologics License Application (BLA) submission for the approval of the combination regimen for commercialization in advanced metastatic breast cancer! “The importance of this milestone speaks for itself and is yet another major step towards our goal to become one of the leading immuno-oncology companies. Jumping directly into a pivotal study shortly after receiving Fast Track status has greatly advanced our lead clinical program timetable with the ultimate goal of commercializing our novel immunotherapy approach for women with no approved treatment options,” said Dr. Williams. Insiders are buying… there’s a current “STRONG BUY” on the stock at both NASDAQ.com and Investing.com… and a nearly $25 price target indicates a potential upside of over 250%! BCTX is zooming in on an unmet need in healthcare and could potentially have something revolutionary! Could Bria-IMT one day be FDA approved? Now is the time to have BCTX on your radar! =========================================================== Copyright 2023 © SCDalerts.com is owned and operated by the owner of SCD Media LLC. Disclaimer and Privacy For more Information please contact info@smallcapsdaily.com This website provides information about the stock market and other investments. This website does not provide investment advice and should not be used as a replacement for investment advice from a qualified professional. This website is for informational purposes only. The Author of this website is not a registered investment advisor and does not offer investment advice. You, the reader, bear responsibility for your own investment decisions and should seek the advice of a qualified securities professional before making any investment. Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security. SCD Media, its managers, its employees, affiliates, and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above. To the maximum extent permitted by law, the Company disclaims all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete, or unreliable, or result in any investment or other losses. You received this message as part of your subscription to SCD Alerts. SCD Alerts is a financial news and information website. We do not directly sell any products or offer any personal financial advice, nor do we advocate the purchase or sale of any security or investment for any specific individual. We also do not make any guarantee or warranty about what is advertised above. If you have questions or concerns about a product you’ve seen in one of our emails, we encourage you to reach out to that company directly. Disclaimer – Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated, and edited by SCD Media. Any wording found in this e-mail or disclaimer referencing “I” or “we” or “our” or “SCD” refers to SCD Media. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore unqualified to give investment recommendations. Companies with low prices per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader to take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and its owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares, we will list the information relevant to the stock and the number of shares here. We do not own any shares in BCTX. We have been currently compensated up to Twenty Five Thousand Dollars Cash ($25,000) via bank wire transfer from a third-party IA Media, LLC for a 1 Day Marketing Program regarding BCTX with a start date of 6/27/2023. SCD’s business model is to receive financial compensation to promote public companies. This compensation is a major conflict of interest in our ability to be unbiased regarding our alerts. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non- compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, SCD often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Small Caps Daily 1334 Northampton St Easton, PA 18042 © 2023 | All rights reserved. [Unsubscribe](~/AASl5QA~/RgRmfUY3P0SoaHR0cHM6Ly9tYW5hZ2Uua21haWwtbGlzdHMuY29tL3N1YnNjcmlwdGlvbnMvdW5zdWJzY3JpYmU_YT1UYTlyaEwmYz0wMUdBUDRURDdWWFhaQlBQQ0o4WTNSS1FCOCZrPTM5YzgyMGVlMjY3Y2RjYjM0YjQxMWVmMGM1NmY1MWE5Jm09MDFIM1g2NFo5NVkxTkVKUFlGVFpDU0VHU1omcj1ZdXdHZm14VwNzcGNCCmSRN8GaZNQuvyZSG3RyaXN0cmFtYmFsZHdpbjg5QGdtYWlsLmNvbVgEAAXhsQ~~). [Twitter] [Facebook] [Instagram]